Evidence map›Paper›PMID 42842081›Full record

ReviewCerebellum (London, England)2026

Parkinsonism with Reduced Striatal Uptake on DAT-SPECT in a Patient Harboring a Novel KCND3 Variant.

Kimitaka Katanazaka, Mariko Takata, China Kanai, Sayaka Matsumoto, Kento Matoba, Mayumi Otani, Shusuke Koto, Kenji Sekiguchi, Yuji Takahashi, Hidehiro Mizusawa and 1 more

Abstract readCase ReportsReview
In one paragraph

Review in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kimitaka KatanazakaDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan. katana@med.kobe-u.ac.jp.ORCID https://orcid.org/0009-0008-7000-0221
Mariko TakataDepartment of Neurology, Kitaharima Medical Center, Ono, Hyogo, 675-1392, Japan.
China KanaiFaculty of Medicine, Kobe University, Kobe, Hyogo, 650-0017, Japan.
Sayaka MatsumotoDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan.
Kento MatobaDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan.
Mayumi OtaniDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan.
Shusuke KotoDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan.
Kenji SekiguchiDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan.ORCID http://orcid.org/0000-0003-4100-7316
Yuji TakahashiDepartment of Neurology, National Center Hospital, National Center of Neurology and Psychiatry (NCNP), Kodaira, Tokyo, 187-8502, Japan.
Hidehiro MizusawaDepartment of Neurology, National Center Hospital, National Center of Neurology and Psychiatry (NCNP), Kodaira, Tokyo, 187-8502, Japan.
Norio ChiharaDivision of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650- 0017, Japan.ORCID http://orcid.org/0000-0003-4499-0790

Funding

AMED-JCAT program funded by the Japan Agency for Medical Research and Development (AMED) JP21ek0109532/JP24ek0109734HK²-MIRAI program funded by AMED JP256f0137011
6 · The paper itself

Abstract

KCND3 encodes the voltage-gated potassium channel Kv4.3, and pathogenic variants in KCND3 are associated with spinocerebellar ataxia type 19/22 (SCA19/22) and related neurological phenotypes. Here, we report a Japanese patient harboring a novel KCND3 missense variant, classified as a variant of uncertain significance, who presented with a clinical phenotype compatible with SCA19/22, including slowly progressive cerebellar ataxia beginning in childhood, accompanied by asymmetric parkinsonism. Dopamine transporter single-photon emission computed tomography demonstrated reduced striatal uptake. Parkinsonian symptoms exhibited a partial response to dopaminergic therapy; however, the improvement was primarily based on clinical observation, with limited objective evidence supporting treatment efficacy. To our knowledge, abnormal dopamine transporter imaging has not been previously reported in patients with SCA19/22-related phenotypes. Although it was difficult to determine whether the parkinsonism was attributable to the KCND3 variant or to coexisting Lewy body disease, we reviewed the literature on parkinsonism associated with SCA19/22 and discussed the potential contributions of both pathologies in the present case.

Indexed as

Corpus StriatumDopamine Plasma Membrane Transport ProteinsParkinsonian DisordersShal Potassium ChannelsDopaminergic ImagingFemaleHumansMaleMutation, MissenseSpinocerebellar DegenerationsTomography, Emission-Computed, Single-PhotonDopamine Plasma Membrane Transport ProteinsKCND3 protein, humanShal Potassium ChannelsDAT-SPECTKCND3Kv4.3ParkinsonismSpinocerebellar ataxia type 19/22

Identifiers

PMID42842081
PMCPMC13645843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.